TW200503694A - Triazole-derivatives as factor Xa inhibitors - Google Patents

Triazole-derivatives as factor Xa inhibitors

Info

Publication number
TW200503694A
TW200503694A TW093113794A TW93113794A TW200503694A TW 200503694 A TW200503694 A TW 200503694A TW 093113794 A TW093113794 A TW 093113794A TW 93113794 A TW93113794 A TW 93113794A TW 200503694 A TW200503694 A TW 200503694A
Authority
TW
Taiwan
Prior art keywords
factor
compounds
formulae
inhibitors
triazole
Prior art date
Application number
TW093113794A
Other languages
English (en)
Chinese (zh)
Inventor
Marc Nazare
Volker Laux
Armin Bauer
Michael Wagner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of TW200503694A publication Critical patent/TW200503694A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW093113794A 2003-05-19 2004-05-17 Triazole-derivatives as factor Xa inhibitors TW200503694A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011309A EP1479679A1 (en) 2003-05-19 2003-05-19 Triazole-derivatives as factor Xa inhibitors

Publications (1)

Publication Number Publication Date
TW200503694A true TW200503694A (en) 2005-02-01

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093113794A TW200503694A (en) 2003-05-19 2004-05-17 Triazole-derivatives as factor Xa inhibitors

Country Status (12)

Country Link
EP (2) EP1479679A1 (enExample)
JP (1) JP4608495B2 (enExample)
AT (1) ATE394396T1 (enExample)
AU (1) AU2004238498B2 (enExample)
BR (1) BRPI0410763A (enExample)
CA (1) CA2526082C (enExample)
DE (1) DE602004013577D1 (enExample)
IL (1) IL171843A (enExample)
MX (1) MXPA05012058A (enExample)
PE (1) PE20050154A1 (enExample)
TW (1) TW200503694A (enExample)
WO (1) WO2004101555A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
PT2000465E (pt) * 2006-03-24 2011-02-10 Eisai R&D Man Co Ltd Derivado de triazolona
EA017250B1 (ru) * 2007-07-19 2012-11-30 Х. Лундбекк А/С 5-членные гетероциклические амиды и их применение для модуляции рецептора p2x
EP2202231A4 (en) 2007-09-21 2011-09-28 Eisai R&D Man Co Ltd 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
AU2011238616B2 (en) 2010-03-30 2016-08-04 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
HUE042393T2 (hu) 2013-03-15 2019-06-28 Verseon Corp Multiszubsztituált aromás vegyületek, mint szerinproteáz inhibitorok
CN110423221A (zh) * 2013-03-15 2019-11-08 维颂公司 作为凝血酶抑制剂的卤代吡唑
EA033168B1 (ru) 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
RU2017112739A (ru) 2014-09-17 2018-10-17 Версеон Корпорейшн Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN112055713A (zh) 2018-03-01 2020-12-08 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
WO1999032454A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
EP1479679A1 (en) 2004-11-24
EP1628971A1 (en) 2006-03-01
IL171843A (en) 2010-12-30
JP4608495B2 (ja) 2011-01-12
BRPI0410763A (pt) 2006-08-01
EP1628971B1 (en) 2008-05-07
MXPA05012058A (es) 2006-06-23
PE20050154A1 (es) 2005-04-29
CA2526082A1 (en) 2004-11-25
DE602004013577D1 (de) 2008-06-19
JP2006528941A (ja) 2006-12-28
CA2526082C (en) 2012-07-24
AU2004238498B2 (en) 2010-07-22
ATE394396T1 (de) 2008-05-15
AU2004238498A1 (en) 2004-11-25
WO2004101555A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
MXPA04004797A (es) Indol-2-carboxamidas como inhibidores del factor xa.
TW200510400A (en) Indazole-derivatives as factor Xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
TW200510393A (en) New indole derivatives as factor Xa inhibitors
WO2005085239A3 (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
PL362519A1 (en) Oxybenzamides derivatives as factor xa inhibitors
YU89202A (sh) Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
MXPA03011022A (es) Derivados de urea con actividad antiproteolitica.
TW200503694A (en) Triazole-derivatives as factor Xa inhibitors
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TW200503696A (en) Benzimidazole-derivatives as factor Xa inhibitors
TW200510411A (en) Azaindole-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors